A novel strategy for the manufacture of idelalisib: controlling the formation of an enantiomer

A novel and scalable synthesis of 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone, idelalisib 1, has been developed. This strategy controls the desfluoro impurity of 13 during reduction of nitro intermediate 4, and also arrests the formation of the enantiomer during cycli...

Descripción completa

Detalles Bibliográficos
Autores principales: Mekala, Nagaraju, Buddepu, Srinivasa Rao, Dehury, Sanjay K., Moturu, Krishna Murthy V. R., Indukuri, Sunil Kumar V., Vasireddi, Umamaheswara Rao, Parimi, Atchuta R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2018
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080089/
https://www.ncbi.nlm.nih.gov/pubmed/35539498
http://dx.doi.org/10.1039/c8ra00407b

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080089/
https://www.ncbi.nlm.nih.gov/pubmed/35539498
http://dx.doi.org/10.1039/c8ra00407b

Ejemplares similares